TRIP6

Across TCGA pan-cancer cohorts, TRIP6 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TRIP6 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TRIP6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRIP6 expression acts as an unfavorable survival marker, although some lineages such as PDAC and OV show a favorable association.

CCRCC, UCEC, and PDAC are the cancer types where TRIP6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	II,III,IV	0.157	0.972	.006	28	view →
UCEC	OS	Median	II,III,IV	0.609	1.000	.008	28	view →
PDAC	DFS	Median	All	0.494	0.338	.012	5	view →
OV	DFS	Tertile	All	1.000	0.801	.037	4	view →
GBM	DFS	Median	All	0.646	0.840	.007	3	view →
LUAD	OS	Tertile	All	1.000	0.904	.022	2	view →
HNSC	DFS	Median	III,IV	0.939	1.000	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TRIP6–CCRCC (DFS)

Open the CCRCC breakdown →